Tango Therapeutics (TNGX) Cash & Equivalents (2020 - 2026)

Tango Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $157.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 170.11% year-over-year to $157.8 million; the TTM figure through Mar 2026 stood at $157.8 million (up 170.11% YoY), while the FY2025 annual figure was $112.3 million, up 55.73% from the prior year.
• Cash & Equivalents was $157.8 million for Q1 2026 at Tango Therapeutics, up from $112.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $157.8 million in Q1 2026 to a low of $39.3 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $75.1 million across 5 years, with a median of $61.2 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents tumbled 58.65% in 2022, then jumped 170.11% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $60.0 million in 2022, then advanced by 10.7% to $66.4 million in 2023, then climbed by 8.6% to $72.1 million in 2024, then soared by 55.73% to $112.3 million in 2025, then surged by 40.57% to $157.8 million in 2026.
• The last three Cash & Equivalents figures came in at $157.8 million (Q1 2026), $112.3 million (Q4 2025), and $58.3 million (Q3 2025), per Business Quant data.